RU2722179C2 - Лечение состояний, ассоциированных с гиперинсулинемией - Google Patents

Лечение состояний, ассоциированных с гиперинсулинемией Download PDF

Info

Publication number
RU2722179C2
RU2722179C2 RU2016138027A RU2016138027A RU2722179C2 RU 2722179 C2 RU2722179 C2 RU 2722179C2 RU 2016138027 A RU2016138027 A RU 2016138027A RU 2016138027 A RU2016138027 A RU 2016138027A RU 2722179 C2 RU2722179 C2 RU 2722179C2
Authority
RU
Russia
Prior art keywords
alkyl
alkylene
aryl
substituted
group
Prior art date
Application number
RU2016138027A
Other languages
English (en)
Russian (ru)
Other versions
RU2016138027A3 (US07846941-20101207-C00217.png
RU2016138027A (ru
Inventor
Стивен Б. ЛАНДАУ
Майкл КЭЙДЖИ
Original Assignee
Тэнша Терапеутикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Тэнша Терапеутикс, Инк. filed Critical Тэнша Терапеутикс, Инк.
Publication of RU2016138027A publication Critical patent/RU2016138027A/ru
Publication of RU2016138027A3 publication Critical patent/RU2016138027A3/ru
Application granted granted Critical
Publication of RU2722179C2 publication Critical patent/RU2722179C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
RU2016138027A 2014-02-28 2015-02-27 Лечение состояний, ассоциированных с гиперинсулинемией RU2722179C2 (ru)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201461946682P 2014-02-28 2014-02-28
US61/946,682 2014-02-28
US201462019777P 2014-07-01 2014-07-01
US62/019,777 2014-07-01
US201462054620P 2014-09-24 2014-09-24
US62/054,620 2014-09-24
PCT/US2015/018118 WO2015131113A1 (en) 2014-02-28 2015-02-27 Treatment of conditions associated with hyperinsulinaemia

Publications (3)

Publication Number Publication Date
RU2016138027A RU2016138027A (ru) 2018-04-03
RU2016138027A3 RU2016138027A3 (US07846941-20101207-C00217.png) 2018-10-29
RU2722179C2 true RU2722179C2 (ru) 2020-05-28

Family

ID=52693055

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016138027A RU2722179C2 (ru) 2014-02-28 2015-02-27 Лечение состояний, ассоциированных с гиперинсулинемией

Country Status (12)

Country Link
US (1) US10925881B2 (US07846941-20101207-C00217.png)
EP (1) EP3110424A1 (US07846941-20101207-C00217.png)
JP (2) JP2017506666A (US07846941-20101207-C00217.png)
KR (1) KR20160130778A (US07846941-20101207-C00217.png)
CN (1) CN106456653A (US07846941-20101207-C00217.png)
AU (1) AU2015222805B2 (US07846941-20101207-C00217.png)
CA (1) CA2940472A1 (US07846941-20101207-C00217.png)
IL (1) IL247354B (US07846941-20101207-C00217.png)
MX (1) MX2016011160A (US07846941-20101207-C00217.png)
RU (1) RU2722179C2 (US07846941-20101207-C00217.png)
SG (1) SG11201607108XA (US07846941-20101207-C00217.png)
WO (1) WO2015131113A1 (US07846941-20101207-C00217.png)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012029057A2 (pt) 2010-05-14 2020-10-13 Dana-Farber Cancer Institute, Inc. composições e métodos de tratamento de leucemia
EP2902030B1 (en) 2010-05-14 2016-09-14 Dana-Farber Cancer Institute, Inc. Thienotriazolodiazepine compounds for treating neoplasia
US11446309B2 (en) 2013-11-08 2022-09-20 Dana-Farber Cancer Institute, Inc. Combination therapy for cancer using bromodomain and extra-terminal (BET) protein inhibitors
RU2016134947A (ru) 2014-01-31 2018-03-01 Дана-Фарбер Кансер Институт, Инк. Производные диаминопиримидин бензолсульфона и их применение
JP2017504651A (ja) 2014-01-31 2017-02-09 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド ジアゼパン誘導体の使用
WO2015131113A1 (en) 2014-02-28 2015-09-03 Tensha Therapeutics, Inc. Treatment of conditions associated with hyperinsulinaemia
WO2016069578A1 (en) 2014-10-27 2016-05-06 Tensha Therapeutics, Inc. Bromodomain inhibitors
MA42249A (fr) 2015-06-26 2018-05-02 Tensha Therapeutics Inc Traitement de carcinome de la ligne médiane nut
RU2750164C2 (ru) 2015-09-11 2021-06-22 Дана-Фарбер Кэнсер Инститьют, Инк. Цианотиенотриазолодиазепины и пути их применения
BR112018004617A2 (pt) * 2015-09-11 2018-09-25 Dana Farber Cancer Inst Inc acetamida tienotriazoldiazepinas e usos das mesmas
CR20180336A (es) 2015-11-25 2018-08-06 Dana Farber Cancer Inst Inc Inhibidores de bromodominio bivalentes y usos de los mismos
EP3555059A1 (en) * 2016-12-16 2019-10-23 H. Hoffnabb-La Roche Ag Process for the manufacture of diazepine derivatives
CN111094263A (zh) * 2017-09-14 2020-05-01 豪夫迈·罗氏有限公司 可用于制造药物的新化合物
MX2020013608A (es) 2018-06-13 2021-03-09 Worg Pharmaceuticals Hangzhou Co Ltd Preparacion de derivados de triazepina condensados y su uso como inhibidores de bet.
CN111253871A (zh) * 2020-03-13 2020-06-09 东莞市永益诚电子有限公司 一种钢化膜及其制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2143424C1 (ru) * 1995-06-06 1999-12-27 Пфайзер Инк. Замещенные n-(индол-2-карбонил)-глицинамиды и их производные, способы лечения и фармкомпозиция
RU2159613C2 (ru) * 1995-06-06 2000-11-27 Пфайзер Инк. ЗАМЕЩЕННЫЕ N-(ИНДОЛ-2-КАРБОНИЛ)-β-АЛАНИНАМИДЫ И ИХ ПРОИЗВОДНЫЕ, СПОСОБ ЛЕЧЕНИЯ ГЛИКОГЕНФОСФОРИЛАЗОЗАВИСИМЫХ ЗАБОЛЕВАНИЙ, СПОСОБ ПРЕДУПРЕЖДЕНИЯ ИШЕМИЧЕСКОГО ПОВРЕЖДЕНИЯ МИОКАРДА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ
US7015213B1 (en) * 1998-06-15 2006-03-21 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Use of diazepines for preparing medicines for treating pathological conditions or diseases involving one of the growth hormone release inhibiting factor receptors
WO2011054844A1 (en) * 2009-11-05 2011-05-12 Glaxosmithkline Llc Condensed azepine derivatives as bromodomain inhibitors
US20130252331A1 (en) * 2010-05-14 2013-09-26 James Elliott Bradner Compositions and methods for modulating metabolism

Family Cites Families (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2951540A (en) 1956-11-05 1960-09-06 Gen Motors Corp Propeller brake
US3709898A (en) 1971-02-09 1973-01-09 Upjohn Co Process for the production of triazolobenzodiazepines and intermediates
US3681343A (en) 1971-05-11 1972-08-01 Upjohn Co 6-phenyl-s-triazolo{8 4,3-a{9 {8 1,4{9 {0 benzodiazepines
US3812259A (en) 1971-08-09 1974-05-21 Upjohn Co Animal feed and process
CH622019A5 (en) 1975-10-23 1981-03-13 Upjohn Co Process for the preparation of aminotriazolobenzodiazepines
FR2329668A1 (fr) 1975-10-27 1977-05-27 Upjohn Co Procede de preparation d'aminotriazolobenzodiazepines
EP0087850A1 (en) 1982-01-04 1983-09-07 The Upjohn Company Benzodiazepines for anti-hypertensive use
DE3435973A1 (de) 1984-10-01 1986-04-10 Boehringer Ingelheim KG, 6507 Ingelheim Diazepine enthaltende pharmazeutische zusammensetzungen mit paf-antagonistischer wirkung
DE3724164A1 (de) 1986-07-25 1988-01-28 Boehringer Ingelheim Kg Neue 1,4-benzodiazepine, ihre herstellung und verwendung
US4960770A (en) 1987-05-28 1990-10-02 Yoshitomi Pharmaceutical Industries, Ltd. 2-alkyl thieno(triazolo)diazepine compounds and pharmaceutical uses thereof
JPH0676326B2 (ja) 1988-05-24 1994-09-28 吉富製薬株式会社 循環器系疾患治療薬
EP0368175A1 (de) 1988-11-06 1990-05-16 Boehringer Ingelheim Kg 3S,7S-3-(Morpholinocarbonyl)-5-(2-chlorphenyl)-7,10-dimethyl-3,4-dihydro-2H,7H-cyclopenta[4,5]thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin.
EP0387613A1 (de) 1989-03-03 1990-09-19 Boehringer Ingelheim Kg Neue Thienodiazepine
EP0407955A1 (de) 1989-07-12 1991-01-16 Boehringer Ingelheim Kg Neue Hetrazepine mit PAF-antagonistischer Wirkung, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE4010528A1 (de) 1990-04-02 1991-10-17 Boehringer Ingelheim Kg Praeparativ chromatographisches trennverfahren zur herstellung enantiomerenreiner hetrazepine
EP0638560A4 (en) 1991-10-11 1995-03-29 Yoshitomi Pharmaceutical MEDICINE FOR OSTEOPOROSIS AND DIAZEPINE COMPOUND *.
EP0661284A1 (en) 1992-09-18 1995-07-05 Yoshitomi Pharmaceutical Industries, Ltd. Thienodiazepine compound and medicinal use thereof
EP0692483A1 (en) 1993-03-30 1996-01-17 Yoshitomi Pharmaceutical Industries, Ltd. Cell adhesion inhibitor and thienotriazolodiazepine compound
WO1995032963A1 (fr) 1994-06-01 1995-12-07 Yoshitomi Pharmaceutical Industries, Ltd. Compose de thienylazole et compose de thienotriazolodiazepine
DK0801651T3 (da) 1995-01-06 2001-10-22 Hoffmann La Roche Hydroxymethyl-imidazodiazepiner og deres estere
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
CA2230477A1 (en) 1995-09-09 1997-03-13 F. Hoffmann-La Roche Ag Use of a thienotriazolodiazepine to increase apolipoprotein a-i levels
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
EP0934940A1 (en) 1996-06-12 1999-08-11 Japan Tobacco Inc. Cytokine production inhibitors, triazepine compounds, and intermediates thereof
US5693641A (en) 1996-08-16 1997-12-02 Berlex Laboratories Inc. Bicyclic pyrimidine derivatives and their use as anti-coagulants
EA001732B1 (ru) 1996-09-13 2001-08-27 Велфайд Корпорейшн Тиенотриазолодиазепиновые соединения и лекарственное средство
US6444664B1 (en) 1997-04-18 2002-09-03 Nederlandse Organisatie Voor Toegepast - Natuurweten Schappelijk Onderzoek (Tno) Method for controlling the plasma level of lipoproteins to treat alzheimeris disease
JPH11228576A (ja) 1997-12-10 1999-08-24 Japan Tobacco Inc アポトーシス抑制剤
IT1298087B1 (it) 1998-01-08 1999-12-20 Fiderm S R L Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
KR20000016732A (en) 1998-12-12 2000-03-25 Japan Tobacco Inc Cytokine production inhibitors, triazepine compounds, and intermediates thereof
EE200100603A (et) 1999-05-14 2003-02-17 Imclone Systems Incorporated Inimese refraktaarsete kasvajate ravi epidermaalse kasvufaktori retseptori antagonistidega
US6312215B1 (en) 2000-02-15 2001-11-06 United Technologies Corporation Turbine engine windmilling brake
US7589167B2 (en) 2000-02-22 2009-09-15 J. David Gladstone Institutes ZA loops of bromodomains
AU2001264303A1 (en) 2000-06-16 2001-12-24 Mitsubishi Pharma Corporation Compositions controlling release ph range and/or speed
US6552037B2 (en) 2000-06-30 2003-04-22 Neurogen Corporation 2-Substituted imidazo[1,2-A]pyridine derivatives
US20060142257A1 (en) 2001-01-19 2006-06-29 Eberhard Nieschlag Male contraceptive formulation comprising norethisterone
US6979682B2 (en) 2001-02-23 2005-12-27 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Platelet-activating factor antagonist inhibition of angiogenesis and tumor growth induced by basic fibroblast
US20030216758A1 (en) 2001-12-28 2003-11-20 Angiotech Pharmaceuticals, Inc. Coated surgical patches
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
US6861422B2 (en) 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
MXPA05009151A (es) 2003-02-27 2005-10-20 Abbott Lab Inhibidores de cinasa heterociclica.
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
US20070111933A1 (en) 2003-06-02 2007-05-17 Kopchick John J Diagnosis and treatment methods related to aging, especially of liver
WO2005002526A2 (en) 2003-07-01 2005-01-13 President And Fellows Of Harvard College Method and compositions for treatment of viral infections
CN100584832C (zh) 2003-09-18 2010-01-27 诺瓦提斯公司 可用于治疗增殖性病症的2,4-二(苯基氨基)嘧啶类
EP1528056A1 (en) 2003-10-29 2005-05-04 Academisch Ziekenhuis bij de Universiteit van Amsterdam Deoxynojirimycin analogues and their uses as glucosylceramidase inhibitors
US20060035903A1 (en) 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US20060074088A1 (en) 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
US7759485B2 (en) 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
CN1759834B (zh) 2004-09-17 2010-06-23 中国医学科学院医药生物技术研究所 黄连素或其与辛伐他汀联合在制备用于预防或治疗与血脂有关疾病或症状的产品中用途
US8624027B2 (en) 2005-05-12 2014-01-07 Abbvie Inc. Combination therapy for treating cancer and diagnostic assays for use therein
JP5159305B2 (ja) 2005-05-30 2013-03-06 田辺三菱製薬株式会社 チエノトリアゾロジアゼピン化合物及びその医薬としての用途
CA2617589A1 (en) 2005-08-03 2007-02-08 Boehringer Ingelheim International Gmbh Dihydropteridinones in the treatment of respiratory diseases
US8604042B2 (en) 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
US8133900B2 (en) 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
US7528143B2 (en) 2005-11-01 2009-05-05 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
WO2007056117A1 (en) 2005-11-04 2007-05-18 Wyeth Antineoplastic combinations of temsirolimus and sunitinib malate
KR20080083680A (ko) 2005-12-23 2008-09-18 스미스클라인 비참 코포레이션 오로라 키나제의 아자인돌 억제제
CN101370807B (zh) 2006-01-17 2011-08-31 弗·哈夫曼-拉罗切有限公司 可用于经由gaba受体治疗阿尔茨海默病的芳基-异唑-4-基-咪唑并[1,2-a]吡啶
DE602007008837D1 (de) 2006-02-14 2010-10-14 Vertex Pharma Als protein-kinase-inhibitoren nutzbare dyhydrodiazepine
US20070218135A1 (en) 2006-03-14 2007-09-20 Glenmark Pharmaceuticals Limited Sustained release matrix pharmaceutical composition
JP2009535425A (ja) 2006-05-03 2009-10-01 ノバルティス アクチエンゲゼルシャフト 有機化合物の使用
US7621117B2 (en) 2006-06-19 2009-11-24 Pratt & Whitney Canada Corp. Apparatus and method for controlling engine windmilling
RU2478635C2 (ru) 2006-10-19 2013-04-10 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Гетероарильные соединения, содержащие их композиции и способы лечения с применением этих соединений
WO2008066887A2 (en) 2006-11-30 2008-06-05 Albert Einstein College Of Medicine Of Yeshiva University Small molecule inhibitors of bcl6
EP2474525B1 (en) 2006-12-26 2020-04-15 Lantheus Medical Imaging, Inc. Ligands for imaging cardiac innervation
JP2008156311A (ja) 2006-12-26 2008-07-10 Institute Of Physical & Chemical Research Ｂｒｄ２ブロモドメイン結合剤
WO2008137081A1 (en) 2007-05-02 2008-11-13 The Trustees Of Columbia University In The City Of New York Substituted ( 5, 6 ) -dihydronaphraalenyl compounds as reversible male contraceptives
KR20080107050A (ko) 2007-06-05 2008-12-10 울산대학교 산학협력단 항-ｃｄ１３７ 단일클론 항체를 포함하는 만성이식편대숙주 질환의 예방 또는 치료용 약학적 조성물
EP2234986A2 (en) 2007-12-20 2010-10-06 Cellzome Limited Sulfamides as zap-70 inhibitors
WO2009084693A1 (ja) 2007-12-28 2009-07-09 Mitsubishi Tanabe Pharma Corporation 抗癌剤
WO2009084692A1 (ja) * 2007-12-28 2009-07-09 Nippon Telegraph And Telephone Corporation 可変焦点レンズ
CA2717529A1 (en) 2008-03-11 2009-09-17 Cellzome Limited Sulfonamides as zap-70 inhibitors
WO2010015340A1 (en) 2008-08-06 2010-02-11 Bayer Schering Pharma Aktiengesellschaft Daa-pyridine as peripheral benzodiazepine receptor ligand for diagnostic imaging and pharmaceutical treatment
AU2009309691B2 (en) 2008-10-30 2015-04-02 Circomed Llc Thienotriazolodiazepine derivatives active on apo A
EP3255047B1 (en) 2009-01-06 2021-06-30 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone kinase scaffold compounds and uses in treating disorders
CN102341394B (zh) 2009-01-23 2015-04-15 武田药品工业株式会社 聚(adp-核糖)聚合酶(parp)抑制剂
GB0919431D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB0919432D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Use
GB0919434D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB0919423D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
KR101424989B1 (ko) 2009-11-05 2014-07-31 글락소스미스클라인 엘엘씨 벤조디아제핀 브로모도메인 억제제
WO2011054845A1 (en) 2009-11-05 2011-05-12 Glaxosmithkline Llc Benzodiazepine bromodomain inhibitor
US8862173B2 (en) 2009-12-10 2014-10-14 Motorola Solutions, Inc. Method for selecting media for delivery to users at an incident
JP5841548B2 (ja) 2010-02-17 2016-01-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ジヒドロプテリジノン、その製造方法及び使用
EP2553251B1 (en) 2010-03-26 2018-11-07 Rolls-Royce North American Technologies, Inc. Adaptive fan system for a variable cycle turbofan engine
CA2799381A1 (en) 2010-05-14 2011-11-17 Dana-Farber Cancer Institute, Inc. Male contraceptive compositions and methods of use
EP2902030B1 (en) 2010-05-14 2016-09-14 Dana-Farber Cancer Institute, Inc. Thienotriazolodiazepine compounds for treating neoplasia
BR112012029057A2 (pt) 2010-05-14 2020-10-13 Dana-Farber Cancer Institute, Inc. composições e métodos de tratamento de leucemia
JP5715241B2 (ja) 2010-05-14 2015-05-07 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド 新生物、炎症性疾患、およびその他の障害を治療するための組成物および方法
WO2011161031A1 (en) 2010-06-22 2011-12-29 Glaxosmithkline Llc Benzotriazolodiazepine compounds inhibitors of bromodomains
MX2013000320A (es) 2010-06-25 2013-06-05 Shire Human Genetic Therapies Composiciones y metodos para suministro al sistema nervioso central de heparan n-sulfatasa.
US20120014979A1 (en) 2010-07-16 2012-01-19 Alexander Dent Use of bcl6 inhibitors for treating autoimmune diseases
TWI549955B (zh) 2010-08-04 2016-09-21 達納 法柏癌症學院有限公司 治療腫瘤形成、發炎疾病及其他病症之組成物及方法
DK2621282T3 (da) * 2010-09-28 2020-05-04 Univ California Gaba-agonister i behandlingen af forstyrrelser forbundet med metabolisk syndrom og gaba-kombinationer i behandling eller profylakse af type i diabetes
AR084070A1 (es) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
US9249161B2 (en) 2010-12-02 2016-02-02 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
US20130004481A1 (en) 2011-01-12 2013-01-03 Boehringer Ingelheim International Gmbh Anticancer therapy
CA2828212A1 (en) 2011-02-23 2012-08-30 Shiraz Mujtaba Inhibitors of bromodomains as modulators of gene expression
WO2012118812A2 (en) 2011-02-28 2012-09-07 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
WO2012119095A1 (en) 2011-03-02 2012-09-07 Board Of Regents, The University Of Texas System Fus1/tusc2 therapies
WO2013019710A1 (en) 2011-07-29 2013-02-07 The Children's Hospital Of Philadelphia Compositions and methods for the treatment of hiv
WO2013033268A2 (en) 2011-08-29 2013-03-07 Coferon, Inc. Bivalent bromodomain ligands, and methods of using same
WO2013033269A1 (en) 2011-08-29 2013-03-07 Coferon, Inc. Bioorthogonal monomers capable of dimerizing and targeting bromodomains and methods of using same
FI20110279A0 (fi) 2011-08-29 2011-08-29 Outotec Oyj Menetelmä metallien talteenottamiseksi niitä sisältävästä materiaalista
WO2013033420A1 (en) 2011-08-30 2013-03-07 Whitehead Institute For Biomedical Research Methods of downregulating translocated oncogene expression using bromodomain inhibitors
DE102011082013A1 (de) 2011-09-01 2013-03-07 Bayer Pharma AG 6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine
WO2013097052A1 (en) 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
CN109529026A (zh) 2012-02-17 2019-03-29 安迅生物制药公司 用于治疗流感和副流感患者的方法、化合物和组合物
WO2013148197A1 (en) 2012-03-28 2013-10-03 The J. David Gladstone Institutes Compositions and methods for reactivating latent immunodeficiency virus
EP2861255B1 (en) 2012-06-19 2019-10-09 The Broad Institute, Inc. Diagnostic and treatment methods in subjects having or at risk of developing resistance to cancer therapy
WO2014068402A2 (en) 2012-09-28 2014-05-08 Oncoethix Sa Pharmaceutical formulation containing thienotriazolodiazepine compounds
EP2917203B1 (en) 2012-11-02 2019-04-03 Dana-Farber Cancer Institute, Inc. Method for identifying myc inhibitors
CA2901799A1 (en) 2013-02-22 2014-08-28 Bayer Pharma Aktiengesellschaft Pyrrolo- and pyrazolo-triazolodiazepines as bet-protein inhibitors for treating hyperproliferative diseases
US20150376196A1 (en) 2013-02-22 2015-12-31 Bayer Pharma Aktiengesellschaft 4-substituted pyrrolo- and pyrazolo-diazepines
WO2014134583A2 (en) 2013-02-28 2014-09-04 Washington University Methods of treatment of human cytomegalovirus infection and diseases with bromodomain inhibitors
US9714946B2 (en) 2013-03-14 2017-07-25 Dana-Farber Cancer Institute, Inc. Bromodomain binding reagents and uses thereof
JP2016519672A (ja) 2013-03-15 2016-07-07 ジェネンテック， インコーポレイテッド ブロモドメイン含有タンパク質ｂｒｄ７およびｂｒｄ９の阻害によるｔｈ２媒介性疾患の治療
CA2913741A1 (en) 2013-05-28 2014-12-04 The Brigham And Women's Hospital, Inc. Bet inhibition therapy for heart disease
DE102013106353B4 (de) 2013-06-18 2018-06-28 Tdk Corporation Verfahren zum Aufbringen einer strukturierten Beschichtung auf ein Bauelement
BR112016001457A2 (pt) 2013-07-25 2017-08-29 Dana Farber Cancer Inst Inc Inibidores de fatores de transcrição e usos dos mesmos
WO2015018522A1 (en) 2013-08-06 2015-02-12 Oncoethix Sa Bet-bromodomain inhibitor shows synergism with several anti-cancer agents in pre-clinical models of diffuse large b-cell lymphoma (dlbcl)
WO2015018521A1 (en) 2013-08-06 2015-02-12 Oncoethix Sa Method of treating diffuse large b-cell lymphoma (dlbcl) using a bet-bromodomain inhibitor
WO2015023938A1 (en) 2013-08-16 2015-02-19 Rana Therapeutics, Inc. Epigenetic regulators of frataxin
US8988212B2 (en) 2013-08-22 2015-03-24 GM Global Technology Operations LLC Electric vehicle pedestrian warning system
US10739333B2 (en) 2013-09-19 2020-08-11 Dana-Farber Cancer Institute, Inc. Methods of BH3 profiling
BR112016007891A2 (pt) 2013-10-11 2017-12-05 Constellation Pharmaceuticals Inc uso de inibidores de bromodomínio cbp/ep300 para imunoterapia do câncer
US11446309B2 (en) 2013-11-08 2022-09-20 Dana-Farber Cancer Institute, Inc. Combination therapy for cancer using bromodomain and extra-terminal (BET) protein inhibitors
WO2015081284A1 (en) 2013-11-26 2015-06-04 Coferon, Inc. Bivalent bromodomain ligands, and methods of using same
JP2017504651A (ja) 2014-01-31 2017-02-09 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド ジアゼパン誘導体の使用
RU2016134947A (ru) 2014-01-31 2018-03-01 Дана-Фарбер Кансер Институт, Инк. Производные диаминопиримидин бензолсульфона и их применение
MX2016009976A (es) 2014-01-31 2016-11-15 Dana Farber Cancer Inst Inc Derivados de diazepam y sus usos.
WO2015131113A1 (en) 2014-02-28 2015-09-03 Tensha Therapeutics, Inc. Treatment of conditions associated with hyperinsulinaemia
WO2016069578A1 (en) 2014-10-27 2016-05-06 Tensha Therapeutics, Inc. Bromodomain inhibitors
KR20170101913A (ko) 2014-12-05 2017-09-06 에이치 리 모피트 캔서 센터 앤드 리서어치 인스티튜트 아이엔씨 암 면역치료의 보조제로서의 브로모도메인 억제제
MA42249A (fr) 2015-06-26 2018-05-02 Tensha Therapeutics Inc Traitement de carcinome de la ligne médiane nut
EP3355922A2 (en) 2015-10-02 2018-08-08 Dana Farber Cancer Institute, Inc. Combination therapy of bromodomain inhibitors and checkpoint blockade

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2143424C1 (ru) * 1995-06-06 1999-12-27 Пфайзер Инк. Замещенные n-(индол-2-карбонил)-глицинамиды и их производные, способы лечения и фармкомпозиция
RU2159613C2 (ru) * 1995-06-06 2000-11-27 Пфайзер Инк. ЗАМЕЩЕННЫЕ N-(ИНДОЛ-2-КАРБОНИЛ)-β-АЛАНИНАМИДЫ И ИХ ПРОИЗВОДНЫЕ, СПОСОБ ЛЕЧЕНИЯ ГЛИКОГЕНФОСФОРИЛАЗОЗАВИСИМЫХ ЗАБОЛЕВАНИЙ, СПОСОБ ПРЕДУПРЕЖДЕНИЯ ИШЕМИЧЕСКОГО ПОВРЕЖДЕНИЯ МИОКАРДА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ
US7015213B1 (en) * 1998-06-15 2006-03-21 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Use of diazepines for preparing medicines for treating pathological conditions or diseases involving one of the growth hormone release inhibiting factor receptors
WO2011054844A1 (en) * 2009-11-05 2011-05-12 Glaxosmithkline Llc Condensed azepine derivatives as bromodomain inhibitors
US20130252331A1 (en) * 2010-05-14 2013-09-26 James Elliott Bradner Compositions and methods for modulating metabolism

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HEDRINGTON M.S. et al. "Effects of Antecedent GABAa Activation With Alprazolam on Counterregulatory Responses to Hypoglycemia in Healthu Humans". Diabetes, 2010, Vol.59,April, 1074-1081. *
БАЛАБОЛКИН М.И. "Инсулинорезистентность и ее значение в патогенезе нарушений углеводного обмена и сахарного диабета типа 2". Сахарный диабет. Пленарные лекции, 2002, no.1, с.12-20. *
БАЛАБОЛКИН М.И. "Инсулинорезистентность и ее значение в патогенезе нарушений углеводного обмена и сахарного диабета типа 2". Сахарный диабет. Пленарные лекции, 2002, no.1, с.12-20. HEDRINGTON M.S. et al. "Effects of Antecedent GABAa Activation With Alprazolam on Counterregulatory Responses to Hypoglycemia in Healthu Humans". Diabetes, 2010, Vol.59,April, 1074-1081. *

Also Published As

Publication number Publication date
MX2016011160A (es) 2017-04-27
AU2015222805A1 (en) 2016-09-15
IL247354A0 (en) 2016-11-30
WO2015131113A1 (en) 2015-09-03
AU2015222805B2 (en) 2020-05-21
KR20160130778A (ko) 2016-11-14
CN106456653A (zh) 2017-02-22
CA2940472A1 (en) 2015-09-03
JP6629947B2 (ja) 2020-01-15
RU2016138027A3 (US07846941-20101207-C00217.png) 2018-10-29
SG11201607108XA (en) 2016-09-29
EP3110424A1 (en) 2017-01-04
US20170209461A1 (en) 2017-07-27
JP2017506666A (ja) 2017-03-09
JP2019059751A (ja) 2019-04-18
IL247354B (en) 2020-06-30
US10925881B2 (en) 2021-02-23
RU2016138027A (ru) 2018-04-03

Similar Documents

Publication Publication Date Title
RU2722179C2 (ru) Лечение состояний, ассоциированных с гиперинсулинемией
JP6782255B2 (ja) ヒストンデアセチラーゼ阻害薬及び組成物並びにそれらの使用の方法
US10124009B2 (en) Bromodomain inhibitors
JP2020023528A (ja) ヒストンデアセチラーゼ阻害剤
US9133139B2 (en) Fluoroalkyl-1,4-benzodiazepinone compounds
TW202014186A (zh) 作為核轉運調節劑之化合物及其用途
US11753412B2 (en) Treatment of cognitive and mood symptoms in neurodegenerative and neuropsychiatric disorders with Alpha5-containing GABAA receptor agonists
JP2019512474A (ja) シアノ置換インドール化合物およびｌｓｄ１阻害剤としてのその使用
AU2021200164A1 (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
JP2016534069A (ja) Ｈｄａｃ６阻害剤での多嚢胞性疾患の治療
JP6805172B2 (ja) ヒストンデアセチラーゼ阻害薬及び組成物並びにそれらの使用の方法
WO2013134371A1 (en) Methods and compounds to be used in the treatment of neurodegenerative diseases
ES2911416T3 (es) Derivados heterocíclicos de sulfonamida y medicamentos que los contienen
JP2023524361A (ja) Ｔｙｋ２活性を阻害する複素環式化合物
CN112409376A (zh) 一种基于dcaf15的蛋白降解靶向嵌合体及其制备方法和应用
CA2916419A1 (en) Substituted 2, 3-dihydro-1h-inden-1-one retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis
JP6542236B2 (ja) 有機化合物
CN114181277A (zh) 一种用于雄激素受体蛋白靶向降解的嵌合体化合物、其制备方法及其在医药上的应用
CN111108083B (zh) 氨基亚甲基环己烷1,3-二酮化合物的用途
JP6118892B2 (ja) デュオカルマイシン類縁体の環式プロドラッグ
TW201922690A (zh) 環－amp反應元素結合蛋白的抑制劑
JP2020502283A (ja) インドールアミン−２，３−ジオキシゲナーゼ阻害剤としてのスルホニルアミディーン及びその製造方法と用途
KR102628396B1 (ko) 샤프롱-매개 자가포식 조절제로서 유용한 화합물
WO2020059841A1 (ja) プリオン病治療薬
TW202334148A (zh) 用於治療弗里德希氏共濟失調（ｆｒｉｅｄｒｅｉｃｈ＇ｓ ａｔａｘｉａ）之化合物及方法